Alternating R ‐CHOP and R‐cytarabine is a safe and effective regimen for transplant‐ineligible patients with a newly diagnosed mantle cell lymphoma
This study was registered at GovTrial (clinicaltrials.gov) NCT03054883. (Source: Hematological Oncology)
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Pavel Klener, Eva Fronkova, David Belada, Kristina Forsterova, Robert Pytlik, Marketa Kalinova, Martin Simkovic, David Salek, Heidi Mocikova, Vit Prochazka, Petra Blahovcova, Andrea Janikova, Jana Markova, Ales Obr, Adela Berkova, Jozef Kubinyi, Martina V Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Prompt detection of L ‐asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas
(Source: Hematological Oncology)
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Fabio Guolo, Mariella Ferrari, Paola Minetto, Cristina Matteo, Marino Clavio, Elisa Coviello, Filippo Ballerini, Maurizio Miglino, Marco Gobbi, Maurizio D'Incalci, Roberto Massimo Lemoli, Massimo Zucchetti Tags: LETTER TO THE EDITOR Source Type: research
Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences?
Abstract
The aim of this retrospective cohort study was to investigate the incidence of delayed methotrexate elimination in patients treated with high‐dose methotrexate (≥1 g/m2) for haematological malignancy and to identify the impact of interacting drugs, especially proton‐pump inhibitors (PPIs) and ranitidine. All patients treated with high‐dose methotrexate over a 6 year period in the haematology department of the Lyon Sud University Hospital (Hospices Civils de Lyon, France) were included. Potential risk factors for delayed methotrexate elimination were tested in a generalized linear model by univariate anal...
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Florence Ranchon, Nicolas Vantard, Emilie Henin, Emmanuel Bachy, Cl émentine Sarkozy, Lionel Karlin, Fadhela Bouafia‐Sauvy, Aurore Gouraud, Verane Schwiertz, Estelle Bourbon, Amandine Baudouin, Anne Gaelle Caffin, Thierry Vial, Gilles Salles, Catherine Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia
Abstract
Light chain amyloidosis is characterized by the progressive deposition of immunoglobulin light chains into the extracellular tissue, leading to organ dysfunction. Usually, it is associated with an underlying clonal plasma cell dyscrasia and rarely with chronic lymphocytic leukaemia. Herein, we described the first report of a patient with relapsed chronic lymphocytic leukaemia harbouring TP53 abnormalities who developed, histologically proven, systemic light chain amyloidosis who was treated with the PI3K inhibitor, idelalisib, and rituximab. Unfortunately, the patient had sudden death during sleep, likely caused b...
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Andrea Visentin, Chiara Briani, Silvia Imbergamo, Federica Frezzato, Annalisa Angelini, Marny Fedrigo, Mario Cacciavillani, Sara Altinier, Francesco Piazza, Gianpietro Semenzato, Fausto Adami, Livio Trentin Tags: LETTER TO THE EDITOR Source Type: research
Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome
Abstract
POEMS syndrome is a rare paraneoplastic condition, with a poorly understood pathogenesis. High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been reported to be an effective therapeutic option for patients with good performance status. Here, we review the role of ASCT for POEMS syndrome and discuss indications together with advantages and disadvantages, and related issues such lenalidomide given before or after ASCT, VEGF levels as a marker of disease, and different regimens for stem cell mobilization. (Source: Hematological Oncology)
Source: Hematological Oncology - September 1, 2017 Category: Hematology Authors: Francesco Autore, Idanna Innocenti, Marco Luigetti, Nicola Piccirillo, Federica Sora, Patrizia Chiusolo, Simona Sica, Andrea Bacigalupo, Luca Laurenti Tags: REVIEW Source Type: research
Splicing variant profiles and single nucleotide polymorphisms of the glucocorticoid receptor gene in relation to glucocorticoid sensitivity of B ‐cell precursor acute lymphoblastic leukaemia
Hematological Oncology,Volume 36, Issue 1, Page 245-251, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 29, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 245-251, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 29, 2017 Category: Hematology Source Type: research
Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case ‐based approach
Hematological Oncology,Volume 36, Issue 1, Page 258-261, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 25, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 258-261, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 25, 2017 Category: Hematology Source Type: research
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B ‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma)
Hematological Oncology,Volume 36, Issue 1, Page 62-67, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 22, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 62-67, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 22, 2017 Category: Hematology Source Type: research
Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma
Hematological Oncology,Volume 36, Issue 1, Page 363-365, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 8, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 363-365, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 8, 2017 Category: Hematology Source Type: research
IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma
Hematological Oncology,Volume 36, Issue 1, Page 196-201, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 7, 2017 Category: Hematology Source Type: research
---
Hematological Oncology,Volume 36, Issue 1, Page 196-201, February 2018. (Source: Hematological Oncology)
Source: Hematological Oncology - August 7, 2017 Category: Hematology Source Type: research
